Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Krina Patel(The University of Texas MD Anderson Cancer Center), Ciara L. Freeman(Moffitt Cancer Center), Tara Gregory(Colorado Blood Cancer Institute), Omar Nadeem(Harvard University), Tim Pulham(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Paola Neri(University of Calgary), Shinsuke Iida(Nagoya City University Hospital), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Susan Bal(University of Alabama at Birmingham Hospital), Sarah Johnston(Bristol-Myers Squibb (United States)), Sarah Larson(APLA Health), Nikhil Munshi, Svenja Groeneveld(Bristol-Myers Squibb (United States)), Jaclyn Davis(Bristol-Myers Squibb (United States)), Julia Piasecki(Université Paris Cité), Anupama Kumar(University of California, San Francisco)
Cited by 0
Related Papers
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430